KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Novavax (NVAX) Cost of Revenue (2022 - 2025)

Novavax (NVAX) has 9 years of Cost of Revenue data on record, last reported at $22.1 million in Q4 2025.

  • For Q4 2025, Cost of Revenue fell 39.72% year-over-year to $22.1 million; the TTM value through Dec 2025 reached $73.0 million, down 63.97%, while the annual FY2025 figure was $73.0 million, 63.97% down from the prior year.
  • Cost of Revenue reached $22.1 million in Q4 2025 per NVAX's latest filing, up from $21.5 million in the prior quarter.
  • Across five years, Cost of Revenue topped out at $434.6 million in Q3 2022 and bottomed at $14.1 million in Q1 2025.
  • Average Cost of Revenue over 4 years is $95.1 million, with a median of $51.0 million recorded in 2023.
  • The widest YoY moves for Cost of Revenue: up 124.19% in 2023, down 79.42% in 2023.
  • A 4-year view of Cost of Revenue shows it stood at $181.8 million in 2022, then dropped by 14.74% to $155.0 million in 2023, then crashed by 76.34% to $36.7 million in 2024, then crashed by 39.72% to $22.1 million in 2025.
  • Per Business Quant database, its latest 3 readings for Cost of Revenue were $22.1 million in Q4 2025, $21.5 million in Q3 2025, and $15.3 million in Q2 2025.